Published: Apr 14, 2021 By Mark Terry
Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based
Eli Lilly and Company inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. SciNeuro picked up an exclusive license to the antibodies developed by Lilly.
Under the terms of the deal, SciNeuro is paying Lilly cash upfront as well as various milestone payments and royalties. No financial details were disclosed. Lilly will hold all rights outside Greater China.
Alpha-synuclein is primarily found in neural tissue. Among other things, it is believed to contribute to Parkinson’s disease.
Chinese drug maker SciNeuro Pharma raises $100m co-led by LAV, Arch Venture Partners Premium
SciNeuro Pharmaceuticals, a Chinese manufacturer of drugs for central nervous system (CNS) diseases, said that it has garnered $100 million in a Series A round funding jointly led by Lilly Asia Ventures (LAV) and Arch Venture Partners.
Continue reading this story with a subscription to DealStreetAsia.
Contact us for corporate subscriptions at subs@dealstreetasia.com.
Sign up for our newsletter - The Daily Brief Opt out of receiving The Daily Brief in your inbox everyday
REGISTER stories left placeholder You have one free story left this month.